On June 30, 2020 CEL-SCI Corporation (NYSE American: CVM) reported that, during the quarter ending June 30, 2020 it has received approximately $10 million from the exercise of warrants (Press release, Cel-Sci, JUN 30, 2020, View Source [SID1234561586]). These funds will allow the Company to complete the expansion of its Multikine* (Leukocyte Interleukin, Inj.) cancer immunotherapy manufacturing facility near Baltimore, MD in anticipation of BLA submission and subsequent marketing approval.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!